TY - JOUR
T1 - Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer
AU - Amini-Vaughan, Zhaleh J.
AU - Martinez-Moczygemba, Margarita
AU - Huston, David P.
N1 - Funding Information:
Acknowledgment This work is supported in part by National Institutes of Health grants R01 AI036936 and U19 AI071130.
PY - 2012/10
Y1 - 2012/10
N2 - The eosinophil is a multifunctional granulocyte best known for providing host defense against parasites. Paradoxically, eosinophils are also implicated in the pathogenesis of allergic inflammation, asthma, and hypereosinophilic syndromes. Emerging evidence also supports the potential for harnessing the cytotoxic power of eosinophils and redirecting it to kill solid tumors. Central to eosinophil physiology is interleukin-5 (IL-5) and its receptor (IL-5R) which is composed of a ligand-specific alpha chain (IL-5Rα) and the common beta chain (βc). Eosinophil activation can lead to their degranulation, resulting in rapid release of an arsenal of tissue-destructive proinflammatory mediators and cytotoxic proteins that can be both beneficial and detrimental to the host. This review discusses eosinophil immunobiology and therapeutic strategies for targeting of IL-5 and IL-5R, as well as the potential for harnessing eosinophil cytotoxicity as a tumoricide.
AB - The eosinophil is a multifunctional granulocyte best known for providing host defense against parasites. Paradoxically, eosinophils are also implicated in the pathogenesis of allergic inflammation, asthma, and hypereosinophilic syndromes. Emerging evidence also supports the potential for harnessing the cytotoxic power of eosinophils and redirecting it to kill solid tumors. Central to eosinophil physiology is interleukin-5 (IL-5) and its receptor (IL-5R) which is composed of a ligand-specific alpha chain (IL-5Rα) and the common beta chain (βc). Eosinophil activation can lead to their degranulation, resulting in rapid release of an arsenal of tissue-destructive proinflammatory mediators and cytotoxic proteins that can be both beneficial and detrimental to the host. This review discusses eosinophil immunobiology and therapeutic strategies for targeting of IL-5 and IL-5R, as well as the potential for harnessing eosinophil cytotoxicity as a tumoricide.
KW - Allergic inflammation
KW - Anti-IL-5 antibodies
KW - Anti-IL-5R antibodies
KW - Asthma
KW - Cancer
KW - Eosinophil
KW - Eosinophilic syndromes
KW - Hypereosinophilic disorders
KW - IL-5 receptor (IL-5R)
KW - Interleukin-5 (IL-5)
KW - Therapeutic
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84870482467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870482467&partnerID=8YFLogxK
U2 - 10.1007/s11882-012-0290-3
DO - 10.1007/s11882-012-0290-3
M3 - Article
C2 - 22875242
AN - SCOPUS:84870482467
SN - 1529-7322
VL - 12
SP - 402
EP - 412
JO - Current Allergy and Asthma Reports
JF - Current Allergy and Asthma Reports
IS - 5
ER -